Mr. Rob Harris reports

TRIBUTE PHARMACEUTICALS RECEIVES URACYST PATENT IN EUROPE

Tribute Pharmaceuticals Canada Inc. has received a patent approval from the European Patent Office (EPO) for intellectual property central to one of the company's lead products, Uracyst/Uropol (a sterile sodium chondroitin sulphate solution, 2 per cent), for the treatment of interstitial cystitis by instillation into the bladder of a patient. Treatments of other bladder disorders are also covered by the patent, including glycosaminoglycan-deficient (GAG) forms of cystitis or GAG deficiency, such as, accompanying chronic urinary tract infection, radiation-induced cystitis, chemical-induced cystitis or hemorrhagic cystitis. The European patent coverage extends to drug compositions comprising a unit dose of chondroitin sulphate in an amount of at least 400 milligrams and an aqueous vehicle. This patent will run until Feb. 18, 2024.

The European patent No. 1603578, entitled "Treatment of Interstitial Cystitis with High Dose Chondroitin Sulphate," will be the ninth high-dose patent granted on Uracyst/Uropol around the world. Currently, the company has high-dose patents granted in the United States, Canada, Japan, Australia and China. There are also high-dose patents pending in several other countries.

Rob Harris, Tribute's president and chief executive officer, commented: "This European patent was granted just weeks after the fourth U.S. patent was issued and further expands the scope of Tribute's exclusive rights in Europe for Uracyst/Uropol and further validates the innovative nature of Tribute's approach to the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). Uracyst/Uropol are sold extensively throughout Europe by Tribute's partners and this patent approval will have significant meaning to each of them. The company is also developing plans to maximize the value of this unique product in the United States and other territories throughout the world where Uracyst/Uropol are currently not marketed."

We seek Safe Harbor.